Company News-Novamab

Our Story

The latest information

Our Story

News

Novamab's LQ036 Receives FDA "Safe to Proceed" for Phase Ib COPD Study, Marking Dual-Track U.S.-China Clinical Development.

Dr. Yakun Wan, founder of Novamab, was selected as the “Pearl Leading Talent” of Pudong New Area in 2024

Novamab Ranks in the Top 10 Most Promising Biopharma Companies on the Huayi List 2024

Novamab officially announced the completion of nearly 300 million RMB in Series B financing

International Conference and 2024 BIO International Convention

Novamab: LQ036 Completes The First Patient Dosing in Phase IIa Clinical StudyThe First Inhaled Biological Agent in China Provides A New Treatment Option for Asthma Patients

BioCon 2024- "Research Progress of Inhalable VHH antibody Drug Therapy for Asthma" A Brief Discussion on Differentiated Development of Antibody Drugs and Clinical Progress of Novamab

Research Information - The development and scaling up of the production process of Novamab‘s anti TSLP VHH antibody have reached an internationally leading level

Clinical Research Updatate - Novamab Announced the Latest Results of the Phase Ia Clinical Study on Inhaled TSLP VHH antibody Drug LQ043H in Healthy Chinese Subjects

Novamab has completed a round B financing of more than 100 million yuan

The research results of Novamab TROP2-ADC were published in the Journal of Nanobiotechnology!

Total 56 123 4 5 6